Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Sten Stovall
TiGenix CEO Eduardo Bravo outlines group's commercialization plans for CPF candidate Cx601 in Europe and the US.
Asked by Scrip to name two big changes coming pharma's way, Merck KGAA Healthcare CEO Belén Garijo identified artificial intelligence and outcome-based pacts as 'ways of the future'.
Merck KGaA Healthcare CEO Belén Garijo tells the Pink Sheet that outcomes-based reimbursement deals like the one it has done with NHS England “are the way of the future”.
The Dementia Discovery Fund won a $50m private investment from Bill Gates – plus his ringing support to probe beyond the amyloid beta hypothesis in hopes of eventually defeating Alzheimer's.
Novartis says nAMD eye treatment brolucizumab showed further advantages over Eylea in two Phase III studies, reinforcing plans to file in late 2018 for a commercial launch in 2019.
As it ends its pact with UCB, Dermira says it needs to focus on its own top assets and couldn't simultaneously launch Cimzia in psoriasis.